skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Patient considerations in early management of Parkinson’s disease: focus on extended-release pramipexole

Review

(757) Views  (157) Full article downloads

Authors: Salawu FK

Published Date January 2012 Volume 2012:6 Pages 49 - 54
DOI: http://dx.doi.org/10.2147/PPA.S11841

Fatai Kunle Salawu
Division of Neurology, Department of Medicine, Federal Medical Centre Yola, Adamawa State, Nigeria

Abstract: This article reviews the role of an extended-release formulation of pramipexole in the treatment of Parkinson’s disease at an early stage. Pramipexole is a nonergot D2/D3 synthetic aminobenzothiazole derivative that is effective as monotherapy in early disease and as an adjunct to levodopa in patients with motor fluctuations. Although levodopa is the current “gold standard” for treatment of Parkinson’s disease, its effectiveness fades rapidly and its use results in serious motor fluctuations (on-off, wearing-off, freezing, involuntary movements) for most patients with the disease. Pramipexole has selective actions at dopamine receptors belonging to the D2 subfamily, where it possesses full activity similar to dopamine itself. Its preferential affinity for the D3 receptor subtype could contribute to its efficacy in the treatment of both the motor and psychiatric symptoms of Parkinson’s disease. The best approach to medical management of early Parkinson’s disease remains controversial. While enormous progress has been made in the treatment of the disease, challenges still remain. A variety of treatment-related and patient-related factors must be taken into account when making these decisions. The current approach to treatment of early Parkinson’s disease depends in part on individual patient factors, including age, severity and nature of symptoms and their impact, presence of cognitive dysfunction, possible underlying behavioral factors predisposing to impulse control disorders, and other comorbidities. Today, the once-daily extended-release formulation of pramipexole offers the advantages of easy continuous delivery of drug and convenience to patients, particularly early in the disease when monotherapy is the rule. Thus, a new “levodopa-sparing” paradigm for treating Parkinson’s disease may now be possible, whereby patients are initially treated with pramipexole and levodopa is added only as necessary.

Keywords: Parkinson’s disease, treatment, pramipexole, dopamine agonist, motor complications, continuous dopaminergic stimulation








Readers of this article also read:

Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo
Beneficial effect of pramipexole for motor function and depression in Parkinson’s disease
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Methemoglobinemia due to topical pharyngeal anesthesia during endoscopic procedures
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Available and emerging treatments for Parkinson’s disease: a review
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Role and clinical utility of pramipexole extended release in the treatment of early Parkinson's disease